Total trials
84
Active
14
Phase 3
15
Total enrollment
47,993
Pipeline matrix
Showing 22 of 22 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Atezolizumab | — | — | — | — | — | 2 | |
| Alectinib | — | — | — | — | — | 2 | |
| Entrectinib | — | — | — | — | — | 2 | |
| Capmatinib | — | — | — | — | — | 2 | |
| Trastuzumab in combination with pertuzumab | — | — | — | — | — | 1 | |
| Vemurafenib in combination with cobimetinib | — | — | — | — | — | 1 | |
| Dabrafenib in combination with trametinib | — | — | — | — | — | 1 | |
| Vemurafenib | — | — | — | — | — | 1 | |
| Cobimetinib | — | — | — | — | — | 1 | |
| Dabrafenib | — | — | — | — | — | 1 | |
| Trametinib | — | — | — | — | — | 1 | |
| Trastuzumab | — | — | — | — | — | 1 | |
| Pertuzumab | — | — | — | — | — | 1 | |
| HMBD-001 | — | — | — | — | — | 1 | |
| HMBD-001 and enzalutamide | — | — | — | — | — | 1 | |
| TT-702 | — | — | — | — | — | 1 | |
| Darolutamide | — | — | — | — | — | 1 | |
| HTL0039732 | — | — | — | — | — | 1 | |
| HTL0039732 Capsules and atezolizumab | — | — | — | — | — | 1 | |
| ALETA-001 | — | — | — | — | — | 1 | |
| UCB4594 | — | — | — | — | — | 1 | |
| LY3143921 hydrate | — | — | — | — | — | 1 |
Next readouts
- 2025-11
- 2027-02-28
- 2027-06
- 2027-06
- 2028-02
- 2029-10
- 2029-10
- 2029-10
- 2029-10
- 2029-10
Top conditions
- Lymphoma12
- Cancer7
- Colorectal Neoplasms7
- Haematological Malignancy7
- Solid Tumour7
- Breast Cancer7
- Prostate Cancer6
- Unspecified Adult Solid Tumor, Protocol Specific6
Frequently asked questions about Cancer Research UK
- How many clinical trials does Cancer Research UK have on ClinicalTrials.gov?
- Cancer Research UK is listed as the lead sponsor on 84 clinical trials in ClinicalTrials.gov, 14 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Cancer Research UK's trials are in Phase 3?
- 15 of Cancer Research UK's trials are in Phase 3, spread across 22 active drug programs.
- What therapeutic areas does Cancer Research UK focus on?
- Cancer Research UK's most-studied conditions on ClinicalTrials.gov are Lymphoma, Cancer, Colorectal Neoplasms, Haematological Malignancy, Solid Tumour.
- When are Cancer Research UK's next clinical trial readouts?
- Cancer Research UK has 10 upcoming primary-completion readouts tracked here; the soonest is “A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours”, expected around 2025-11.